Director / Sr. Principal Engineer, Shire
Dr. David Geer has worked over 12 years in the biopharmaceutical industry in the areas of process development and commercialization of live virus vaccines and biological drug substances and products. David started his professional career at Merck and Co., Inc with the responsibility for technical support and project leadership during late stage product development. Over the years, he has contributed to many new products serving global unmet medical needs such as GARDASIL®, the first vaccine for cervical cancer and KEYTRUDA®, the first FDA-approved anti PD1 immunotherapy medicine for melanoma and lung cancer. Recently, David joined Shire as a Director in Small Molecule Technical Operations and is currently working in Exton, PA.
David's PhD Advisor was Professor Stelios Andreadis